UW Monkeypox Drug Trial Seeks Volunteers

SEATTLE — UW Medicine researchers are seeking patients with monkeypox infections to participate in a clinical trial for a new drug to help treat the virus. The study is looking to enroll hundreds of adults across the United States to participate in the third phase of a trial for tecovirimat, a federally-approved smallpox drug.

“There is an urgent need for monkeypox treatments, and this study will help us get critical information about the safety and effectiveness of tecovirimat at treating this infection,” said Dr. Rachel Bender Ignacio, assistant professor of allergy and infectious diseases at the University of Washington School of Medicine. “People living in the Seattle area who have monkeypox have the opportunity to make a huge contribution by participating in this study.”

According to the Centers for Disease Control and Prevention, more than 23,000 monkeypox cases in the U.S. are linked to the international outbreak, including nearly 550 in Washington. More than 60,000 cases have been identified in 103 countries.

The monkeypox virus can produce flu-like symptoms, often followed by a rash with bumps. According to public health officials, the disease is rarely deadly, and most people recover in two to four weeks. The JYNNEOS vaccine, while currently limited in supply, can help prevent initial infection and make symptoms less severe.

Patients interested in enrolling in the clinical trial for tecovirimat can contact UW Positive Research by e-mail or call 206-773-7129.

Related: Washington Confirms Pediatric Monkeypox Cases